Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd (ZTEK) delivers cutting-edge innovations in healthcare technology and advanced materials through its patented intellectual property portfolio. This news hub provides investors and industry observers with timely updates on corporate developments, regulatory milestones, and commercial partnerships.
Access verified press releases and analysis covering ZenGUARD™ antimicrobial advancements, battery material research, and strategic collaborations with academic institutions. Our curated feed ensures transparent tracking of financial announcements, product launches, and intellectual property expansions.
Key updates include earnings reports, technology licensing agreements, and progress in graphite purification techniques for energy storage applications. Bookmark this page to monitor Zentek's progress in enhancing medical safety standards and sustainable material solutions.
Zentek (NASDAQ:ZTEK) has completed the first phase of a ~$1.1 million Innovative Solutions Canada contract to develop a countermeasure for highly pathogenic avian influenza (HPAI) A(H5N1). The project, which began in November 2024, involves collaboration with McMaster University's Li Lab to create both prophylactic and therapeutic solutions using multivalent aptamer technology.
The development phase has successfully produced a lead candidate countermeasure that matched the performance of a monoclonal antibody positive control in recent in vitro neutralization experiments. The project is now moving to the testing phase, where the team will evaluate in vivo performance against H1N1 and the current H5N1 2.3.4.4b clade.
The initiative is supported by government testing partners including Health and Emergency Preparedness Canada (HERC) and Defence Research and Development Canada (DRDC), addressing the global avian influenza outbreak that has affected over 1,000 dairy cattle herds across 17 U.S. states.
Zentek (Nasdaq: ZTEK, TSXV: ZEN) has announced the sale of its corporate office and laboratory space located at 24 Corporate Court, Guelph, ON. The property will be sold for $2.5 million under an agreement dated April 15, 2025.
As part of the deal, Zentek will lease back the property until January 31, 2026, ensuring uninterrupted operations during the transition period. The company expects to complete the sale around May 15, 2025, with no anticipated disruption to daily operations or staff. The sale is part of Zentek's strategic review of its portfolio and assets to support long-term business goals.
Zentek (NASDAQ:ZTEK) has successfully completed testing of its ZenARMOR™ nano-pigment technology in military-grade, chromate-free corrosion protection aerospace paint systems under the Innovative Solutions Canada Testing Stream contract. The testing, conducted from September 2023 to July 2024, followed ASTM B117 and ASTM D5894 standards.
The final round of testing subjected samples to 2,016 hours of corrosion testing, with no obvious substrate corrosion or coating defects observed. The tests demonstrated ZenARMOR™'s effectiveness in inhibiting corrosion of aluminum alloy AA2024-T3, though control samples showed similar performance.
Additionally, Zentek announced a new collaboration with Jazeera Paints, signed January 13, 2025. The partnership aims to evaluate ZenARMOR™ nano-pigments in Jazeera's existing product lines, focusing on corrosion protection products in the Gulf Cooperation Council and Middle East and North Africa regions.
Zentek (NASDAQ:ZTEK) has signed a three-year collaboration agreement with Filtration Solutions Industrial Co. (FSCO), a Saudi-based air filtration manufacturer, to produce and distribute ZenGUARD™ Enhanced Air Filters across the Gulf Cooperation Council region.
Under the agreement effective April 11, 2025, Zentek will provide FSCO with HVAC filter media featuring their proprietary graphene-silver-based technology. The filters will be marketed throughout Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, and Oman, with revenue shared between both companies.
The ZenGUARD™ Enhanced Air Filters offer key benefits including:
- Improved viral filtration efficiency
- Reduced energy consumption through lower pressure drop
- Cost-effective protection for public buildings
- Enhanced aerosol control capabilities
Zentek (NASDAQ:ZTEK) has announced the completion of a Canada Revenue Agency (CRA) audit regarding the company's 2018 and 2019 renunciation of Canadian exploration expenses (CEE). The audit, completed on January 14, 2025, focused on flow-through common shares private placements that raised $4,210,000.
The CRA's reassessment for 2018 resulted in a reclassification of approximately $507,000 (16.895%) of renounced amounts, as they did not meet CEE definition requirements. This led to a Part XII.6 tax assessment of $59,693. A similar reclassification is expected for 2019, with details pending.
The company will indemnify affected subscribers within 20 business days for tax attributable to disallowed CEE renunciations, with maximum liability estimated at approximately $527,000. Subscribers affected by CRA reassessments are directed to contact fts@zentek.com for indemnification claims.
Zentek (NASDAQ:ZTEK) has completed important shelf-life efficacy testing for its ZenGUARD™ Enhanced Air Filters, a key requirement for medical device compliance. The testing revealed that after 20 months of aging, the filters maintained consistent performance with an initial viral filtration efficiency (VFE) of 38.1%, comparable to the original 37.7%.
The shedding test results confirmed excellent coating adhesion over the 20-month period, with particle counts remaining within statistical deviation of background levels. Based on these results, ZenGUARD™ Enhanced Air Filters will receive a 20-month expiry date from manufacture.
This milestone follows the November 27, 2024 announcement of manufacturing and selling these filters as a Class I medical device under the company's medical device establishment licence (MDEL). Zentek is now finalizing documentation to support manufacture and sale alongside ZenGUARD™ Surgical Masks, in compliance with Canadian Medical Device Regulations and ISO 13485:2016 standards.
Zentek (NASDAQ: ZTEK) has announced entering into an at-the-market (ATM) offering agreement to issue and sell common shares worth up to US$30 million in the United States. The offering will be conducted through Rodman & Renshaw as the exclusive sales agent.
The shares will be sold directly on the Nasdaq Capital Markets or through market makers, with no sales occurring in Canada. The offering will continue until reaching the US$30 million target or early termination. Share prices will vary based on prevailing market conditions.
The offering is made through a prospectus supplement dated March 3, 2025, to the company's U.S. registration statement on Form F-3, which was declared effective by the SEC on May 3, 2024.
Zentek (NASDAQ:ZTEK) announced new results from fluidized bed reactor (FBR) testwork conducted by its subsidiary Albany Graphite Corp. The tests revealed that rare earth elements (REEs) can be recovered as a by-product during the thermal purification process of graphite.
Key findings show that purification performed on an ~950g sample of Albany flotation concentrate (85% Total Graphitic Carbon) achieved 99.9991% purity without intermediate hydrometallurgical steps. Impurity elements, including REEs, were successfully collected and concentrated in the FBR exhaust scrubber.
The company plans to further investigate the REE potential of the Albany graphite deposit and tailings, while also exploring graphite production for battery-ready anode material, cathode conductivity enhancement, and ultra-high purity graphite for nuclear applications. The Albany Graphite Project is located near Hearst, Ontario, with access to key infrastructure.
Zentek (NASDAQ:ZTEK)(TSXV:ZEN) announced updates on the launch of ZenGUARD™ Enhanced Air Filters in the Canadian market. The company is finalizing documentation for manufacturing and sales under its medical device establishment licence (MDEL), targeting initial sales by end of March 2025.
The company has completed its Innovative Solutions Canada Testing Stream contract, making the product eligible for Government of Canada purchases through the Pathway to Commercialization opportunity. Zentek will showcase the filters at BUILDEX Vancouver on February 26-27, 2025.
The India team is working to promote ZenGUARD™ technology adoption by engaging with HVAC manufacturers and industry leaders. Zentek plans to use its Canadian Class I medical device classification as a foundation for U.S. market entry, with an Environmental Protection Agency application currently under review.
Zentek (NASDAQ:ZTEK) announced that its subsidiary, Albany Graphite (AGC), has achieved ultra-high purity of 99.9991% from its Albany graphite deposit using a pilot-scale fluidized bed reactor (FBR). The purification was performed directly on a ~950g sample of Albany flotation concentrate with 85% Total Graphitic Carbon, eliminating the need for intermediate hydrometallurgical steps.
The process yielded extremely low total impurities of 9 ppm against the industry standard maximum of 500 ppm for advanced battery applications. The company will continue testing the material for lithium-ion battery anode components and nuclear industry applications. Notably, this purification was achieved without using chlorine or halogen gases, which are commonly required for achieving five-nines purity levels.
The Albany Graphite Project, located near Hearst, Ontario, consists of 521 mining claims and is situated within 30 km of the Trans-Canada Highway, with access to established infrastructure including roads, rail, power, and natural gas.
